Study Evaluating the Effect on Gastroduodenal Mucosa of PA32540, PA32540 and Celecoxib, and Aspirin With Celecoxib
Information source: Pozen
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy
Intervention: PA32540 (Drug); PA32540 and celecoxib (Drug); aspirin and [NSAID] (Drug)
Phase: Phase 1
Status: Recruiting
Sponsored by: Pozen Overall contact:
Eric Orlemans, Phone: 919-913-1030
Summary
We will evaluate the effect on the gastroduodenal mucosa from oral dosing of three different
treatments
Clinical Details
Official title: Study Evaluating the Effect on Gastroduodenal Mucosa of PA32540, PA32540 and Celecoxib, and Aspirin With Celecoxib
Study design: Basic Science, Randomized, Open Label, Single Group Assignment, Safety Study
Primary outcome: Lanza scores
Secondary outcome: safety of three treatments
Eligibility
Minimum age: 50 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Healthy male or non-pregnant female subjects greater than or equal to 50 years as well
as other standard inclusion criteria for a study of this nature
Exclusion Criteria:
- Standard exclusion criteria for a study of this nature
Locations and Contacts
Eric Orlemans, Phone: 919-913-1030
Anaheim, California, United States; Recruiting
Additional Information
Starting date: June 2008
Ending date: July 2008
Last updated: June 17, 2008
|
